Your First Clinical Trial: The Supply Decisions a Biotech Should Make Before Submission

A first-time sponsor usually has a brilliant science team, a lean operations team, and a CRO that promises to handle the rest. Clinical supply often lands in the gap between them. The CMC lead assumes the CRO is managing distribution. The CRO assumes the sponsor has a packaging vendor. Then, eight weeks before the planned first patient, someone asks where the labeled kits are.

This is one of the most common ways a small biotech loses a quarter. The fix is not hiring a large department. It is making a handful of decisions early and giving one person the job of owning them.

Name an owner

Clinical supply touches CMC, regulatory, clinical operations, and quality. If nobody owns it end to end, decisions fall between functions. In a small company the owner might be a part-time consultant or a CMC lead with explicit responsibility. What matters is that one person is accountable for drug being at sites, labeled and released, before patients arrive.

Decide what you are actually supplying

Write down every material the trial needs:

• Investigational product, with dose strengths and formulation.
• Placebo, if blinded, and how it will be matched.
• Comparators or background therapy, and whether you supply them or sites do.
• Ancillaries, such as infusion sets, diluents, or devices.

Each item is its own mini supply chain with its own lead times. Comparators and matched placebo in particular can take longer than the drug itself.

Work backward from first patient

Most first-time sponsors plan forward from drug substance. Plan backward instead. Starting from the first patient date, map site shipment, depot receipt, QP or release, labeling and packaging, label text approval, drug product manufacture, and drug substance. Add realistic durations, including vendor scheduling queues that can be months long. The result is usually alarming, and that is the point. You find out now, not later.

Pick vendors for the trial you will run next

It is tempting to choose the cheapest packager and depot for a small Phase 1. But switching vendors between phases means tech transfer, requalification, and lost time right when you want to move fast. If you expect to go global in Phase 2, choose partners who can follow you there. Ask about their country coverage, IRT integrations, and capacity for your likely scale.

Keep the IRT simple and test it

Early trials often do not need complicated IRT configuration, and some Phase 1 studies run on manual processes. If you do use IRT, keep the supply settings simple, document them, and actually test them in UAT. Misconfigured resupply rules are a common cause of early stockouts.

Treat labels as regulatory documents

Label text needs to meet the rules of every country where the kit may go. In the EU that means Annex VI of the Clinical Trials Regulation. In the US it means the caution statement and 21 CFR requirements. Get regulatory sign-off on label text early, because a label change after printing means relabeling under GMP.

Plan for shelf life you do not have yet

Early-stage products often launch with only six or twelve months of stability data. Kits may expire before the study ends unless you extend shelf life as new data comes in. Plan the stability program and relabeling route at the same time, so that an extension can be applied at sites without a scramble.

Budget honestly

First-time sponsors routinely underbudget supply. Beyond manufacturing, include packaging and labeling, storage, distribution, temperature monitoring, comparator purchases, relabeling, returns, destruction, and vendor oversight. A realistic supply budget built early is a much easier conversation with your board than an overrun in the middle of enrollment.